Thanks, Nish. And good morning, everyone. I’d like to take some time to walk through our financial results and to provide more insight into the drivers of performance. Additional information will be available when we file our Form 10-Q with the SEC. Let’s start with a few highlights. The industrial sector continues to gain traction. Industrial end market related core product revenue was up 7% in the quarter and we continue to see good momentum in fall protection and head protection products, both up over 15%, while fixed gas and flame detection is starting to show growth as well, up 11% in the quarter. Gross profit was up 40 basis points year-on-year and while we saw a favourable product mix in the quarter, we were also able to expand product margins across many of our core areas in the quarter. SG&A expense was down $2 million on a reported basis for the quarter and $5 million for the year-to-date period. On a constant currency organic basis, excluding cost related to acquisitions, SG&A is down $3 million in the quarter and $7 million for the year-to-date period. We’re tracking well against out full year cost savings target of $10 million. Free cash flow continues to be healthy and conversion was over 100% of net income in the quarter and over the past 12 months. Even excluding the success we had in collecting our insurance receivables over the past year, the stronger cash flow and profitability that we have seen over the last year provided us with the opportunity to increase our dividend by 6% in May. While at the same time, servicing debt going from 2.5 debt to EBITDA following the Latchways acquisition to 1.2 times at the end of the quarter. We are well positioned to use our excess capacity for growth investments, like the Globe acquisition that Nish just spoke about, which I’ll provide more details on it just a bit. We continue to make great progress in collecting our insurance and notes receivables as well. We collected $22 million in insurance proceeds in the quarter, bringing our total year-to-date collections to $110 million. As I’ve discussed on the calls for several quarters now, we have had great success settling disputed insurance with a number of our carriers. Of course, the side of the insurance receivable is the underlying product liability. As you saw in our press release issued last night, we recorded a $30 million pretax charge related to product liability settlements that we have reached in August 2017, as well as estimated indemnity for all remaining asserted cumulative trauma claims. This charge did not have a cash impact in the quarter. These asserted claims relate the products we sold many, many years ago and were not previously recorded in our reserve. However, we learned more about a significant number of claims throughout the second quarter, including the nature and extent of alleged injury, product ID and other facts that have provided us with a foundation to estimate our potential liability associated with the asserted claims. This charge impacted our GAAP earnings by about $21 million after tax or $0.53 per diluted share. At a high level, the charge of the income statement reflects the total increase to the reserve we took, which was $84 million, net of expected insurance collections and brings our total cumulative trauma reserve to $93 million. Breaking down the $84 billion increase of the reserve, about $75 million of that is related to product liability settlements reached in August that allowed us to resolve a significant number of claims. By settling these claims, we have more certainty around our cash outflows related to this area in the coming years. We will pay $25 million towards these settlements in the second half of 2017 with the balance to be paid equally over seven quarters or about $7 million per quarter, starting in the first quarter of 2018 and ending in the third quarter of 2019. The remaining increase to the reserve reflects estimated indemnity on all other asserted cumulative trauma claims. We are now fully reserved for all ascertain cumulative trauma claims. We do not have a reserve however for unasserted or IBNR claims and in the second half of 2017 we will follow our normal process related to assessing incurred but not reported claims. I'd like to point out the fact that the cash impact to the payment - for the payment of cumulative trauma product liability claims has been reflected in our cash flow statement for more than a decade, as such claims were paid. Due to our ongoing success with respect to collected disputing - the collecting disputed insurance, we currently estimate that we have sufficient cash flow streams that should help fund this liability. Insurance related receivables approximate $186 million today and going forward we intend to utilize cash flows from collections on our insurance receivable to fund the recent settlements and future payments on asserted claims to the extent available. Now let me walk you through the quarterly financial results. Constant currency sales were down 2% in the quarter. As Bill mentioned, softer conditions in the SCBA market in the current year and a difficult comp and ballistic-helmets both weighed on our results. These two areas reduced overall sales by about 6% in the quarter. But offsetting the declines in SCBA and ballistic-helmets were strong improvements in the industrial sector, notably with an head protection, fall protection, increasing 15% and 16% respectively. The order book continues to be solid in these areas, particularly fall protection. While incoming orders continues to be healthy in portable gas detection after posting a strong Q1, we were up against a tough comparison in this area during the second quarter. In fact, Q2 2016 was our strongest quarter for portable gas detection a year ago, reflecting 14$ year-over-year growth. While demand for short cycle industrial products continues to gain traction, we also saw strength in FGFD this quarter, which grew 11% on large order shipments out of the Middle East and during the first half we saw orders come in ahead of our internal plan. Overall, we are pleased with the order pace in FGFD. Looking at non-core sales, which approximates just over 15% of total sales in the quarter, we continue to see weakness in ballistic-helmets. You might recall we had a large contract in 2016 notably across Europe and that has and will present a headwind in non-core revenue again in the third quarter. Gross profit continues to be a bright spot in our results, finishing 40 basis points higher than a year ago. While mix is more favourable, we also saw a good underlying performance with improvements across a broad number of product groups in the quarter. SG&A expense was down 2% or $2 million from a year ago on a reported basis in the quarter and as I mentioned at the beginning of my commentary, constant currency organic SG&A is down $7 million year-to-date. We've seen solid improvements in our cost structure driven by our value creation programs. For example, going back a few years, in the first six months of 2014 before we begin our focus on value creation, our SG&A expense was 30.7% of sales. In the first half of 2015 SG&A was 29.2% of sales. And by 2016 we had started executing on restructuring programs and you saw SG&A come down to 26.9% of sales. In 2017, excluding costs associated with acquisitions, our SG&A was 26.5% of sales. That's over 400 basis points of operating leverage gained in three years through SG&A reductions. Looking forward, we continue to plan for $10 million of cost savings in 2017, as a result of the steps we've taken to reduce our cost structure. While we continue to evaluate additional streamlining opportunities moving forward, we remain highly committed to making investments that drive growth and market share gains in our core product areas, like R&D. We funded those activities at 4.1% of sales in the quarter. We are also levering up to investing growth opportunities like the Globe acquisition, as Nish discussed in his commentary. I'll talk more about the financials related to the deal in just a moment. Back to the income statement review, quarterly GAAP operating income was $14 million, reflecting the product liability charge I discussed a few minutes ago. Adjusted operating income, excluding this charge, restructuring and currency exchange losses was $48 million or 16.5% of sales, relatively flat from a year ago. But it's important to note the strategic transaction costs associated with acquisitions were dilutive to quarterly operating margin by 60 basis points and dilutive to year-to-date operating margins by 50 basis points. Our tax rate this quarter was impacted by the product liability charge that we reported in the quarter and the windfall tax benefit associated with stock compensation I spoke about in the first quarter. Excluding the impact of the windfall benefit, we expect the full year adjusted ETR to approximate 30% to 31% showing nice improvement from a year ago, as we continue to see improvements in the geographic profile profitability. We had quarterly GAAP earnings of $13 million and on an adjusted basis earnings were healthy, up 10% percent to $33 million or $0.85 in the quarter, compared to $0.79 in the same quarter a year ago. Operating cash flow was $50 million in the quarter, compared to $24 million in the same period a year ago, continuing to reflect our ongoing progress in collecting our insurance receivable, partially offset by higher cash used for accounts receivables related to an uptick in sales in June. As I indicated on the April call, we had expected to receive between $20 million and $25 million of insurance proceeds for the remainder of 2017. And in the second quarter we received $22 million of that cash from our insurance carriers. Net of settlement settlements paid inflows related to product liabilities in the quarter were $10 million, compared to net outflows of $27 million in this quarter a year ago. Additionally, we expect at least $25 million of cash flow to be received in 2018 and expect additional amounts to be received in later years. For the year-to-date period, we've collected about $110 million of insurance proceeds. While that activity has certainly helped our cash flow and allowed us to delever quickly, our underlying cash conversion has been strong at over 100 percent. Our debt balance at quarter end was $270 million, reflecting debt payments of $28 million in the quarter and $125 million in the first half. At June 30, our leverage was at 1.2 times EBITDA compared to 1.8 times at year end 2016. We have a strong history of levering up for accretive of acquisitions, including our most recent acquisition of Latchways, where we levered up to 2.5 times and realized earnings accretion of $0.13 per share in year 1. Through our evaluations of inorganic investments, we determined that the acquisition of Globe reflects a solid opportunity to use the balance sheet to drive value. The purchase price for this transaction which closed just a few days ago was $215 million or nine times trailing EBITDA and we financed it with our revolver which carries an after tax interest rate of less than 2%. We expect the acquisition to be accretive to GAAP earnings by $0.10 to $0.15 cents per share and accretive to adjusted earnings by $0.20 to $0.25 per share in the first 12 months of ownership. Now the Globe's revenue was about $110 billion in 2016 and their EBITDA for the last 12 months was about $24 million. Pro forma debt to EBITDA approximates two times. From a strategic and financial standpoint this acquisition is great value generator for MSA shareholders, Globe expands our core product portfolio in an end market where we have a deep history and knowledge, contributes earnings accretion in the first 12 months and creates a cash flow stream that further enables us to support our capital allocation priorities, including growth investments, dividend payments and debt service. Before I turn the call back over to Bill, I wanted to make a few concluding comments. The revenue comparison was challenging in the quarter, but it is encouraging to see industrial products on a continued upward trajectory, double-digit increases in head protection and fall protection, both short cycle industrial products that tend to serve as leading indicators are positive signs as we head into the second half. We still are planning for mid-single digit total revenue growth for 2017 and low single digit growth on an organic basis. Our cost savings programs continue to yield strong results. On an organic constant currency basis, SG&A is down $3 million in the quarter and $7 million in the first six months. The team is doing a great job in increasing efficiency and productivity. And you're seeing the benefits of those efforts in our streamline cost structure and higher incremental operating margin. Our cash flow increased significantly in the quarter and we have delevered from 1.8 times EBITDA at the end of ‘16 to 1.2 times at the end of the quarter. Our strong cash flow in the first half positions us well to use our balance sheet to drive value with the Globe acquisition, which we secured for a purchase price of $250 million or nine times trailing EBITDA. An attractive multiple for a strategic of transaction is expected to contribute between $0.20 and $0.25 per share of adjusted earnings in the next 12 months. In the second quarter, we became largely self-insured for cumulative trauma product liability claims. As a result, you will see product liability outflows hit the income statement in the future. Again, actual outflows have always been in our cash flow statement for more than a decade, but now both reserves and settlements paid will be reflected in earnings. And as we discussed in our disclosures for several quarters now, we expected to be largely self-insured in the near term. While the exact point in time when this transaction would occur was always difficult to predict because it relied on so many different factors. It did occur in the expected timeframe. Furthermore, we are better positioned to fund these liabilities due to our recent success in settling disputed insurance. We currently have $186 million of notes and insurance related receivables. We have recorded $110 million of insurance proceeds year-to-date and expect $25 million of collections for 2018 with more collections in 2019 and beyond on the $186 million of insurance related receivables. We will use inflows from the insurance proceeds to fund the recent settlements, as well as future payments on asserted claims to the extent available. As a result, we do not expect this liability to have any material impact on our current capital allocation priorities. Overall, we are positioned very well heading into the second half. We've made good progress in improving our cost structure and cash flow and investing in acquisitions like Globe to grow our business. Furthermore, our capital structure provides us with the ability to continue to invest in additional growth opportunities going forward. With that, I'll turn - I'll now turn the call back over to Bill for some concluding commentary. Bill?